11.8亿美元!一款国产自免TCE双抗卖了

动脉新医药
Mar 04

今日,香港上市公司德琪医药(Antengene,股票代码:6996.HK)宣布,与比利时生物制药公司优时比(UCB)达成全球独家授权协议,将针对B细胞介导自身免疫疾病的CD19×CD3双特异性T细胞衔接器(TCE)ATG-201的研发、生产和商业化权利授予优时比。根据公告,德琪医药将获得8000万美元(包括6000万美元首付款及2000万美元近期里程碑付款),并有望在未来获得最高超过11亿美元的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10